NYSE:ABBVBiotechs
How AbbVie’s Dermatology Data Push and Humira Discount Strategy Will Impact AbbVie (ABBV) Investors
In late March 2026, AbbVie highlighted extensive new clinical data across its dermatology portfolio at the American Academy of Dermatology meeting, including long-term outcomes for Skyrizi and Rinvoq and investigational results in vitiligo and alopecia areata, underscoring its focus on immune-mediated skin diseases and quality-of-life measures.
Around the same time, AbbVie also moved to broaden access and tighten pricing frameworks by launching Humira at a steep discount on the TrumpRx...